Synergy reaches halfway point in enrolment of plecanatide Phase IIb trial

Biopharmaceutical company Synergy Pharmaceuticals has reached more than half of the enrolment target in Phase IIb trial of guanylate cyclase-C agonist, Plecanatide, in patients with irritable bowel syndrome with constipation (IBS-C).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news